John Jezorwski

发表

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppre

C. Mussini, C. Spinner, G. Huhn, 2020, HIV research & clinical practice.

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients.

D. Podzamczer, J. Rockstroh, C. Orkin, 2019, AIDS.

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TA

C. Orkin, F. Post, S. De Wit, 2019, Antiviral research.

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

E. Negredo, J. Gallant, A. Antinori, 2018, AIDS.

Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)

J. Pérez-Ruixo, O. Ackaert, H. Crauwels, 2021, The AAPS Journal.

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

A. Morrison, M. Saville, T. Wartel, 2016, PLoS neglected tropical diseases.

Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12–13 Months of Age in Colombia and Peru: A Randomized Trial

C. Lanata, A. Gil, H. Verastegui, 2016, The Pediatric infectious disease journal.

Immunogenicity Yellow Fever Vaccine Immune Response

C. Lanata, A. Gil, H. Verastegui, 2022 .

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

M. Buti, M. Biermer, T. Asselah, 2023, The Lancet Gastroenterology & Hepatology.

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

E. Y. Wong, S. De Meyer, A. Ghys, 2019, AIDS research and human retroviruses.

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study

C. Mussini, C. Spinner, E. Y. Wong, 2019, HIV research & clinical practice.

Week 96 resistance analyses of the once‐daily, single‐tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV‐1 from the phase 3 randomized AMBER and EMERALD trials

S. De Meyer, A. Ghys, E. Lathouwers, 2020, Journal of medical virology.